Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 14/20 | 0.73 |
| ▸ | CA9 | Q16790 | 14/20 | 0.73 |
| ▸ | CA1 | P00915 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871758 | 0.90 | STS (0.81) | STSCA2CA9CA1CA12 | |
| SCHEMBL6799582 | 0.78 | STS (0.63) | STSCA2CA9CA1CA12 | |
| SCHEMBL3838706 | 0.77 | STS (0.63) | STSCA2CA9CA1CA12 | |
| SCHEMBL14596833 | 0.77 | STS (0.61) | STSCA2CA9CA1CA12 | |
| SCHEMBL6799239 | 0.77 | STS (0.61) | STSCA2CA9CA1CA12 | |
| SCHEMBL4976876 | 0.76 | CA2 (0.80) | STSCA2CA9CA1 | |
| SCHEMBL6798661 | 0.76 | STS (1.00) | STSCA2CA9CA1 | |
| SCHEMBL9451471 | 0.74 | CA2 (1.00) | STSCA2CA9CA1 | |
| SCHEMBL9451347 | 0.74 | CA2 (1.00) | STSCA2CA9CA1CA12 | |
| SCHEMBL9451224 | 0.74 | CA2 (0.76) | STSCA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030296-B2 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-20060281719-A1 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase | LLOYD POTTER BARRY V | 2006-12-14 | — | — | US | disclosed |
| US-7119081-B2 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2006-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281719-A1 | Oestrogen-17-sulphamates as inhibitors of steroid sulphatase | STS, SULT1E1, HSD17B11 | STS 1/4885CA2 1812/4885CA9 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.